Samuel Ejadi

3.4k citations

34 papers · 1.6k indexed · 1 hit paper · h-index 16

Impact in

Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
Otorhinolaryngology top 2%
- Head and Neck Cancer Studies

Papers in ⓘ

Oncology 21
- Cancer Immunotherapy and Biomarkers 12
- Colorectal Cancer Treatments and Studies 5
- Pancreatic and Hepatic Oncology Research 3
Otorhinolaryngology 2

Co-authors: Sanatan Saraf (5 shared papers)Roger B. Cohen (4 shared papers)Sarina A. Piha‐Paul (6 shared papers)Aaron R. Hansen (4 shared papers)Emilie M.J. van Brummelen (5 shared papers)John M. Wallmark (4 shared papers)Patrick A. Ott (2 shared papers)Caroline Even (3 shared papers)
Journals: Journal of Clinical Oncology (11 papers)Annals of Oncology (6 papers)European Journal of Cancer (5 papers)Molecular Therapy (1 paper)Scientific Reports (1 paper)
Partner nations: United States South Korea Canada

In The Last Decade

Samuel Ejadi

32 papers receiving 1.6k citations

Hit Papers

align trajectories log scale

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study 2017 · 300 citations

Peers

Countries citing papers authored by Samuel Ejadi

Since Specialization

Citations

This map shows the geographic impact of Samuel Ejadi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel Ejadi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel Ejadi more than expected).

Fields of papers citing papers by Samuel Ejadi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel Ejadi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel Ejadi. The network helps show where Samuel Ejadi may publish in the future.

Co-authors

The 25 scholars most cited alongside Samuel Ejadi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Samuel Ejadi Line = papers co-authored together Samuel Ejadi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study Journal of Clinical Oncology ·Chiun Hsu, Se‐Hoon Lee, Samuel Ejadi, Caroline Even, Roger B. Cohen, Christophe Le Tourneau, Janice M. Mehnert, Alain P. Algazi, Emilie M.J. van Brummelen, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Aaron R. Hansen Hit paper breakdown →	2017	300
2	Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study Annals of Oncology ·Aaron R. Hansen, Christophe Massard, Patrick A. Ott, Naomi B. Haas, Juanita Lopez, Samuel Ejadi, John M. Wallmark, Bhumsuk Keam, Jean‐Pierre Delord, Rahul Aggarwal, M. Gould, Peng Yang, Stephen J. O’Keefe, Sarina A. Piha‐Paul	2018	260
3	Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma PLoS ONE ·Bert H. O’Neil, John M. Wallmark, David Lorente, Élena Elez, Judith Raimbourg, Carlos Gomez‐Roca, Samuel Ejadi, Sarina A. Piha‐Paul, Mark N. Stein, Albiruni R. Abdul Razak, Katia Dotti, Armando Santoro, Roger B. Cohen, M. Gould, Sanatan Saraf, Karen Stein, Sae‐Won Han	2017	221
4	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal Annals of Oncology ·Patrick A. Ott, Sarina A. Piha‐Paul, Pamela N. Münster, Michael J. Pishvaian, Emilie M.J. van Brummelen, Roger B. Cohen, Carlos Gomez‐Roca, Samuel Ejadi, Mark N. Stein, Emily Chan, Matteo Simonelli, Anne Morosky, Sanatan Saraf, Kenneth Emancipator, Minori Koshiji, Jaafar Bennouna	2017	164
5	Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape Mayo Clinic Proceedings ·Aleksandar Sekulić, Paul Haluska, Arlo J. Miller, Josep Genebriera De Lamo, Samuel Ejadi, José S. Pulido, Diva R. Salomão, Erik C. Thorland, Richard G. Vile, David C. Swanson, Barbara A. Pockaj, Susan D. Laman, Mark R. Pittelkow, Svetomir N. Markovic	2008	90
6	Mapping the binding site of aflatoxin B1 in DNA: systematic analysis of the reactivity of aflatoxin B1 with guanines in different DNA sequences Biochemistry ·Matt Benasutti, Samuel Ejadi, Marc Whitlow, Edward L. Loechler	1988	83
7	Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial. Journal of Clinical Oncology ·Mary L. Disis, Manish R. Patel, Shubham Pant, Jeffrey R. Infante, A. Craig Lockhart, Karen Kelly, J. Thaddeus Beck, Michael S. Gordon, Glen J. Weiss, Samuel Ejadi, Matthew H. Taylor, Anja von Heydebreck, Kevin M. Chin, Jean-Marie Cuillerot, James L. Gulley	2015	82
8	Phase I/II Study of GM-CSF DNA as an Adjuvant for a Multipeptide Cancer Vaccine in Patients With Advanced Melanoma Molecular Therapy ·Miguel‐Angel Perales, Jianda Yuan, Sarah Powel, Humilidad F. Gallardo, Teresa Rasalan, Christina Gonzalez, Gregor Manukian, Jian Wang, Yan Zhang, Paul B. Chapman, Susan E. Krown, Philip O. Livingston, Samuel Ejadi, Katherine S. Panageas, Manuel E. Engelhorn, Stephanie Terzulli, Alan N. Houghton, Jedd D. Wolchok	2008	76
9	Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study). Journal of Clinical Oncology ·Byoung Chul Cho, Alexander Drilon, Robert C. Doebele, Dong‐Wan Kim, (unknown), Jeeyun Lee, Myung‐Ju Ahn, Viola W. Zhu, Samuel Ejadi, D. Ross Camidge, Yuwei Juliet Liu, Shanna Stopatschinskaja, Jingrong Jean Cui, David M. Hyman, Sai‐Hong Ignatius Ou, Alice T. Shaw	2019	60
10	A phase I/II study of TKM-080301, a PLK1-targeted RNAi in patients with adrenocortical cancer (ACC). Journal of Clinical Oncology ·Michael J. Demeure, Tannaz Armaghany, Samuel Ejadi, Ramesh K. Ramanathan, Aymen Elfiky, Jonathan Strosberg, David C. Smith, Timothy G. Whitsett, Winnie S. Liang, Shobana Sekar, John D. Carpten, Paul Fredlund, Demi Niforos, Andrew Dye, Sarabjit Gahir, Sean C. Semple, Mark Kowalski	2016	45
11	Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study Annals of Oncology ·Aaron R. Hansen, Christophe Massard, P.A. Ott, Naomi B. Haas, Juanita Lopez, Samuel Ejadi, John M. Wallmark, Bhumsuk Keam, Jean‐Pierre Delord, Rahul Aggarwal, M. Gould, Ping Qiu, Sanatan Saraf, Stephen J. O’Keefe, Sarina A. Piha‐Paul	2016	36
12	MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy. Journal of Clinical Oncology ·David S. Hong, Yoon‐Koo Kang, Andrew Brenner, Jasgit C. Sachdev, Samuel Ejadi, Mitesh J. Borad, Tae‐You Kim, Ho Yeong Lim, Keunchil Park, Carlos Becerra, Andreas G. Bader, Jay Stoudemire, Stephen M. Smith, Sinil Kim, Muhammad Shaalan Beg	2016	28
13	Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts Scientific Reports ·Bin Fang, Aarthi Kannan, Stephanie Zhao, Quy Nguyen, Samuel Ejadi, Maki Yamamoto, Jose C. Barreto, Haibo Zhao, Ling Gao	2020	25
14	First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1 Cancer Immunology Immunotherapy ·Amit Mahipal, Samuel Ejadi, Sacha Gnjatic, Seunghee Kim‐Schulze, Hailing Lu, Jan H. ter Meulen, Richard T. Kenney, Kunle Odunsi	2019	22
15	Abstract C43: Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors Molecular Cancer Therapeutics ·Muhammad Shaalan Beg, Andrew Brenner, Jasgit C. Sachdev, Samuel Ejadi, Mitesh J. Borad, Y.-K. Kang, Ho Yeong Lim, Tae‐Yop Kim, Andreas G. Bader, Jay Stoudemire, Stephen M. Smith, Sinil Kim, David S. Hong	2015	18
16	Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology ·John Nemunaitis, Annie Young, Samuel Ejadi, Wilson H. Miller, Lin-Chi Chen, Gwen Nichols, Steven Blotner, Faye Vazvaei, Jianguo Zhi, Albiruni R. Abdul Razak	2018	16
17	502 Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028 European Journal of Cancer ·Bert H. O’Neil, John M. Wallmark, David Lorente, Élena Elez, Judith Raimbourg, Carlos Gomez‐Roca, Samuel Ejadi, Sarina A. Piha‐Paul, Rebecca A. Moss, L. L. Siu, Katia Dotti, Armando Santoro, Milena Gould, Shukai Yuan, Minori Koshiji, SW Han	2015	15
18	315O_PR Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study Annals of Oncology ·Chih‐Hung Hsu, Seung‐Hoon Lee, Samuel Ejadi, Caroline Even, Roger B. Cohen, C. Le Tourneau, J. Mehnert, Alain P. Algazi, Emilie M.J. van Brummelen, Sanatan Saraf, Pradeep Thanigaimani, J. Cheng, Aaron R. Hansen	2015	13
19	500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028 European Journal of Cancer ·P.A. Ott, Sarina A. Piha‐Paul, Pamela N. Münster, Michael J. Pishvaian, Emilie M.J. van Brummelen, Romain Cohen, Carlos Gomez‐Roca, Samuel Ejadi, Matthew K. Stein, E. Ricky Chan, Matteo Simonelli, Anne Morosky, Shukai Yuan, Masatoshi Koshiji, Jaafar Bennouna	2015	12
20	506 Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer European Journal of Cancer ·Jasgit C. Sachdev, Hendrick-Tobias Arkenau, J. R. Infante, M. Mita, S. P. Anthony, Ronald B. Natale, Samuel Ejadi, Keith Wilcoxen, Vikram Kansra, Haley Laken, Lindsey D. Hughes, R. Martell, Glen J. Weiss	2014	12

About Samuel Ejadi

Samuel Ejadi is a scholar working on Oncology, Otorhinolaryngology, Cancer Research, Pulmonary and Respiratory Medicine and Immunology, having authored 34 papers that have together received 1.6k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (12 papers), Immunotherapy and Immune Responses (7 papers), Prostate Cancer Treatment and Research (6 papers), Colorectal Cancer Treatments and Studies (5 papers), Colorectal and Anal Carcinomas (4 papers), Pancreatic and Hepatic Oncology Research (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Melanoma and MAPK Pathways (2 papers). The work is most often cited by research in Oncology (1.1k citations), Otorhinolaryngology (157 citations), Immunology (442 citations), Cancer Research (270 citations) and Pulmonary and Respiratory Medicine (503 citations). Samuel Ejadi has collaborated with scholars based in United States, South Korea and Canada. Frequent co-authors include Sanatan Saraf, Roger B. Cohen, Sarina A. Piha‐Paul, Aaron R. Hansen, Emilie M.J. van Brummelen, John M. Wallmark, Patrick A. Ott, Caroline Even, Alain P. Algazi and Carlos Gomez‐Roca. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Molecular Therapy and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact